GlassScriptPhysician profile
Sierra Dawn Gross
NPI 1649698366
$665.59
in general payments reported to CMS, 2019-2025
16 companies · $56.42 in 2025
The $56.42 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $82.63 · 2021: $134 · 2022: $120 · 2023: $53.74 · 2025: $56.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $115.56 | 2019-2022 | |
| Glaxosmithkline, LLC. | $109.02 | 2019-2022 | |
| Pfizer INC. | $76.93 | 2019-2021 | |
| Lilly USA, LLC | $58.40 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $56.42 | 2025 | Spyglass Discover |
| Sanofi-Aventis U.S. LLC | $42.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $27.65 | 2021-2023 | Airsupra |
| Amgen INC. | $26.78 | 2019-2020 | |
| Abbott Laboratories | $23.63 | 2022 | |
| Abbvie INC. | $22.55 | 2022 | |
| Organon LLC | $21.56 | 2021-2022 | |
| Allergan, INC. | $19.81 | 2019 | |
| Collegium Pharmaceutical, INC. | $18.20 | 2023 | Xtampza |
| Eisai INC. | $17.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.47 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sierra Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.